Skip to main content

Table 1 Tissue microarray identifies the association between XPO1 expression and clinical characteristics in neuroblastoma patients

From: XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Factors Case No XPO1 expression P value
low, No. (%) high, No. (%)
Gender     0.181
  Male 28 16 (57.1) 12 (42.9)  
  Female 36 27 (75.0) 9 (25.0)  
Age (month)     0.019
   ≤ 18 19 17 (89.5) 2 (10.5)  
   > 18 45 26 (57.8) 19 (42.2)  
MYCN amplification     0.016
  No 35 28 (80.0) 7 (20.0)  
  Yes 20 9 (45.0) 11 (55.0)  
Tumor stage (INSS)      < 0.001
  4 s + 1 + 2 29 27 (93.1) 2 (6.9)  
  3 + 4 26 10 (38.5) 16 (61.5)  
Pathological histotype     0.580
  Neuroblastoma 23 14 (60.9) 9 (39.1)  
  Ganglioneuroblastoma 41 29 (70.7) 12 (29.3)  
Preoperative chemotherapy     0.008
  No 31 26 (83.9) 5 (16.1)  
  Yes 33 17 (51.5) 16 (48.5)  
  Death      < 0.001
  No 23 22 (95.7) 1 (4.3)  
  Yes 29 9 (31.0) 20 (69.0)  
  1. Pearson’s chi-squared test and CMH test was used for statistical analysis; INSS International Neuroblastoma Staging System